Accelovance sets up European facility in South Wales
CRO will create 70 highly skilled clinical research jobs in Swansea
US-based contract research organisation (CRO) Accelovance is to set up a new European facility in Swansea, South Wales, creating 70 highly skilled clinical research jobs.
The move follows the Rockville, MD-headquartered company’s acquisition of Altair Clinical (now called Accelovance Europe) in Bury St Edmunds in January, and will complement other offices in Russia and Israel. Accelovance Europe's Managing Director Nigel Trim will oversee the expansion to Swansea.
'This opportunity provided by the Welsh Government will allow us to shift our primary UK operations to Wales, which provides a highly-talented scientific workforce to support the continued growth of Accelovance,' said Jamie Oliver, Executive Director for European and Asian Operations.
The expansion has been made possible with financial support from the Welsh Government.
Economy Minister Edwina Hart said: 'Wales is making a name for itself as a great location for businesses in the life sciences sector and gaining a reputation as a UK hotspot for pharmaceutical services.
'Accelovance is a most welcome addition to the sector, and its presence will enhance our reputation in this particular field. This is a great project for Wales and a significant investment.'
Accelovance is focused primarily on oncology, vaccines, and general medicine. The CRO offers clinical development services including management and implementation of Phase I–IV clinical trials and a Clinical Engagement Solution used for recruitment, post-marketing surveillance, and long-term survival follow-up.
